Age-related macular degeneration (AMD), or the deterioration of the center of the retina, is one of the most common causes of vision loss among seniors. Until now, there has been no way to treat this condition, leaving many seniors without any hope of recovering the vision they've lost or slowing the deterioration. 

Now, there may be a solution to this problem in the form of a new stem cell treatment that has shown promise in rats. Researchers from the Cedars-Sinai Medical Center in Los Angeles used adult human skin cells to create induced neural progenitor stem cells (iNPSCs), which can mature into several different kinds of nerve cells. They then injected these cells into rats who had been modeled for AMD. 

They found that the iNPSCs caused healthy cells to travel to the retina and accumulate around it, creating a protective layer that slowed the decay of the retinal cells involved in AMD. Based on the fact that the rats' vision was preserved for 130 days after just one iNPSC injection, researchers predict that the treatment would last for about 16 years in humans. 

"Though additional preclinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases," said Dr. Clive Svendsen, director of the Board of Governors Regenerative Medicine Institute at Cedars-Sinai.

Based on these results, the researchers plan to set up additional trials to test whether this kind of treatment might be able to have an effect on AMD in its later stages.

For information on stem cell therapies and other anti-aging medicine, contact the Longevity Centres of America today.